
Reset all filters
01 2Trodelvy
02 2Trodelvy - U.S.
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 49
2019 Revenue in Millions : 0
Growth (%) : Acquired by Gilead from Immunomedics
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 380
2020 Revenue in Millions : 49
Growth (%) : 676
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 680
2021 Revenue in Millions : 380
Growth (%) : 79
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,063
2022 Revenue in Millions : 680
Growth (%) : 56